Minor salivary gland carcinoma: a review of 35 cases.
Minor salivary gland carcinomas represent a heterogeneous group of tumors with broad variation in clinical appearance and histopathology. Clinical data of patients with small salivary gland malignancies were collected from the medical records. Tissue microarray was constructed to determine the expression pattern of 24 proteins in 35 patients with minor salivary gland carcinomas. The choice of markers was based on involvement in neoangiogenesis, cell-to-cell contact, cell-cycle regulation and carcinogenesis. Protein expression data were correlated to patients' clinical data. Overexpression of patched (p = 0.046) and Smo (p = 0.032) was linked to a better overall survival and Glutathione S-transferase π overexpression was linked to prolonged disease-free survival (p = 0.005). Cox-1 (p = 0.035) and VEGFR2 (p = 0.009) were significantly linked to decreased survival for recurrent disease. Bcl-x (84 %), β-catenin (87 %) and Cox-2 (87 %) were significantly overexpressed in minor salivary gland carcinomas. We have shown that Smo resulted in a better overall survival, whereas Gstπ in improved disease-free survival. VEGFR2 was a prognostic factor for survival after recurrence in patients with minor salivary gland carcinomas. Cyclooxygenase inhibitors and anti-Wnt-1 antibodies might be a potential therapeutic option in an adjuvant setting or for patients with unresectable tumors of the minor salivary glands.
Department of Otorhinolaryngology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Georg
G
Haymerle
Department of Otorhinolaryngology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Sven
S
Schneider
Department of Otolaryngology, Head and Neck Surgery, University of Toronto, Ontario, Canada.
Luke
L
Harris
Department of Otorhinolaryngology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Theresia
T
Häupl
Department of Head and Neck Surgery, Maxillofacial Surgery, Medical University of Vienna, Vienna, Austria.
Christian
C
Schopper
Department of Clinical Pathology, Medical University of Vienna, Vienna, Austria.
Johannes
J
Pammer
Department of Otorhinolaryngology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria.
Matthaeus Ch
MCh
Grasl
Department of Otorhinolaryngology, Medical University of Vienna, Waehringer Guertel 18-20, 1090, Vienna, Austria. boban.erovic@meduniwien.ac.at.
Boban M
BM
Erovic
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D018572:Disease-Free Survival; D005260:Female; D051549:Glutathione S-Transferase pi / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012468:Salivary Gland Neoplasms / Q000378:metabolism* / Q000401:mortality* / Q000473:pathology; D012470:Salivary Glands, Minor; D000072086:Smoothened Receptor / Q000378:metabolism; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000378:metabolism; D051176:beta Catenin / Q000378:metabolism
C491023:SMO protein, human; D000072086:Smoothened Receptor; D051176:beta Catenin; D051549:Glutathione S-Transferase pi; C000588866:KDR protein, human; D040301:Vascular Endothelial Growth Factor Receptor-2
Anti-Wnt-1 antibodies; Cyclooxygenase; Small salivary gland tumors; Targeted anticancer therapy